Foghorn(R) Therapeutics Inc. (FHTX) announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer, on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas. Before joining Foghorn, Anna most recently held leadership roles at Bristol Myers Squibb (BMY) where she successfully oversaw strategic transactions across immunology, neuroscience, and cardiovascular disease as the Vice President of Business Development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
- Foghorn Therapeutics initiated with a Buy at Jefferies
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Foghorn Therapeutics initiated with an Outperform at Evercore ISI
- Foghorn Therapeutics Unveils August 2024 Investor Presentation